Clinical aspects of coenzyme Q10: An update

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 8, Issue 6, 2005, Pages 641-646

  Littarru, Gian Paolo ^a,b   Tiano, Luca ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Institute of Biochemistry   (Italy)

Author keywords

Age related macular degeneration; Asthenozoospermia; Cardiovascular disease; Coenzyme Q10; Migraine; Mitochondrial dysfunction; Neurodegenerative disorders; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RIBOFLAVIN; SIMVASTATIN; UBIDECARENONE;

ASTHENOSPERMIA; BIOENERGY; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; ENDOTHELIUM CELL; EVALUATION; FATIGUE; FRIEDREICH ATAXIA; HEART FUNCTION; HEART PROTECTION; HUMAN; MIGRAINE; MITOCHONDRIAL MYOPATHY; MITOCHONDRION; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; RETINA MACULA DEGENERATION; REVIEW; RHABDOMYOLYSIS;

ATAXIA;

EID: 27744491181     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000171123.60665.16     Document Type: Review

References (36)

1. Dallner G, Stocker R, Coenzyme Q. In: Encyclopedia of dietary supplements. New York: Marcel Dekker; 2005. pp. 121 -131. A comprehensive yet synthetic review highlighting both the biochemical aspects and clinical implications of coenzyme Q.
2. 10 affects gene expression in vitro.
3. 10.
4. 10 and was conducted with a rigorous double-blind methodology.
5. 10 in human heart disease: part I + II. Int J Vit Nutr Res 1972; 42:291-305 and 413-434.
6. 10 as adjunctive therapy in chronic heart failure. BioFactors 2003; 18:79-89.
7. 10 was probably too low for the severity of the disease.
8. 10 Association; 2005. pp. 57-58. http://www.coenzymeq10. org.
9. 10 in pediatric cardiomyopathy. It is an open-label study lacking a placebo group.
10. 10 in improving metabolic control of triglyceride disorders.
11. 10 in physical exercise, hypertension and heart failure. Biofactors 2003; 18:91-100.
12. 10 and endothelial dysfunction and reporting experimental results obtained in the last 2 years.
13. 10 Association, Los Angeles, California, 14-17 April 2005. pp. 62-63.
14. 10 and statins.
15. 10 and myocardial biooenergetics.
16. 10 and statins can be antiatherogenic. Comparison with a group receiving only statins would give further insight.
17. 10 deficiency. Arch Neurol 2005; 62: 317-320. A single-patient study characterized by sound biochemical evaluation. It highlights the importance of early identification and treatment.
18. 10 improves lactic acidosis, strokelike episodes, and epilepsy in a patient with MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes). Clin Neuropharmacol 2004; 27:187-191. A soundly evaluated single-patient study. It stresses the unpredictable a priori efficacy of therapy.
19. Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990; 100:70-78.
20. 10 administration on oxidative phosphorylation disorders.
21. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59:1541-1550.
22. 10 dosages, suggesting these for future studies.
23. 10 as a potential treatment. J Bioenerg Biomembr 2004; 36:381-386. A comprehensive review.
24. 10 and dopamine agonists.
25. 10 in rescuing some deficiencies of mitochondrial complexes.
26. 10.
27. 10 indicates elevated systemic oxidative stress in Parkinson's disease. J Neurol Sci 2004; 223:161-166. Important contribution to the identification of blood markers of oxidative stress and their relationship to disease.
28. Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich's ataxia: a four-year follow-up. Arch Neurol 2005; 62:621-626. First study on the long-term treatment of FRDA.
29. 10 effect in migraine.
30. 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992; 42:2147-2152.
31. 31P NMR study. Neurology 1989; 39:399-403.
32. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomised controlled trial. Neurology 1998; 50:466-470.
33. 10 as a migraine preventive. Cephalalgia 2002; 22:137-141.
34. 10 dependent or whether it is synergistic.
35. 10 levels in idiopathic and varicocele-associated asthenozoospermia. Andrologia 2002; 34:107-111.
36. 10 increases seminal fluid levels.